McKesson Reports Fiscal 2021 Third-Quarter Results

 Third-Quarter Highlights, Year-over-Year:

• Total revenues of $62.6 billion, reflecting 6% growth.
• McKesson recorded a pre-tax charge of $8.1 billion related to opioid litigation, resulting in third-quarter Loss per diluted share of ($39.03).
• Adjusted Earnings per diluted share of $4.60, an increase of 21%.
• Board of Directors authorized an additional $2.0 billion share repurchase program.

Fiscal 2021 Guidance:

• Increased fiscal 2021 Adjusted Earnings per diluted share guidance range to $16.95 to $17.25, from the previous range of $16.00 to $16.50.
• Fiscal 2021 Adjusted Earnings per diluted share guidance assumes $0.25 to $0.35 related to COVID-19 vaccine distribution and $0.20 to $0.30 related to the kitting and distribution of ancillary supplies for COVID-19 vaccines.

https://www.biospace.com/article/releases/mckesson-reports-fiscal-2021-third-quarter-results/